TheraGenetics to Develop Dx for Alzheimer’s Rx; Running PGx Study With King’s College | GenomeWeb
TheraGenetics last week joined the AddNeuroMed Consortium and penned an agreement with King's College London to conduct a pharmacogenomics study to determine which Alzheimer’s patients will respond to cholinesterase inhibitors.
Out of this PGx study, “the company intends to develop and commercialize a diagnostic for treatment response,” a spokesperson for the London-based firm told Pharmacogenomics Reporter this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.